{
"id":"mk19_a_on_t07",
"number":7,
"bookId":"on",
"title":{
"__html":"International Federation of Gynecology and Obstetrics Ovarian Cancer Staging, Treatment, and Survival"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"205dfa",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 7. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_on_t07"
}
]
},
"International Federation of Gynecology and Obstetrics Ovarian Cancer Staging, Treatment, and Survival"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64c6da",
"class":"col hd l",
"children":[
"Stage"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b890b",
"class":"col hd l",
"children":[
"Definition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c4ac0",
"class":"col hd l",
"children":[
"Treatment"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"629953",
"class":"col hd l",
"children":[
"5-Year Survival"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"63bf80",
"class":"cell txt l",
"children":[
"Stage I disease (favorable)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"673f4b",
"class":"cell txt l",
"children":[
"Cancer in one or both ovaries, not high grade or clear cell, negative peritoneal washings, no rupture"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"49130e",
"class":"cell txt l",
"children":[
"Surgery alone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"525e05",
"class":"cell txt l",
"children":[
"94% overall survival"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b928a8",
"class":"cell txt l",
"children":[
"Stage I disease (unfavorable); stage II disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d77a3a",
"class":"cell txt l",
"children":[
"Unfavorable stage I disease: confined to ovaries but with high-grade or clear cell histology, rupture, or positive peritoneal washings"
]
},
" ",
{
"type":"p",
"hlId":"b64c65",
"class":"cell txt l",
"children":[
"Stage II disease: spread beyond ovaries but confined to pelvis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9fe44a",
"class":"cell txt l",
"children":[
"Surgery followed by 3 to 6 cycles of chemotherapy (usually carboplatin and paclitaxel)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e7b44",
"class":"cell txt l",
"children":[
"Stage I: 85% relative survival",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"8254ce",
"class":"cell txt l",
"children":[
"Stage II: 70%-78% relative survival"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b82ba",
"class":"cell txt l",
"children":[
"Optimally debulked stage III disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba6d4d",
"class":"cell txt l",
"children":[
"Spread to abdomen, with residual tumor masses <1 cm after debulking surgery"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1627f8",
"class":"cell txt l",
"children":[
"Surgery followed by IV or IV/IP chemotherapy"
]
},
" ",
{
"type":"p",
"hlId":"77ea36",
"class":"cell txt l",
"children":[
"Maintenance olaparib after first-line chemotherapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"251a80",
"class":"cell txt l",
"children":[
"IV chemotherapy: 40% overall survival"
]
},
" ",
{
"type":"p",
"hlId":"e736ca",
"class":"cell txt l",
"children":[
"IV/IP chemotherapy: 50% overall survival (23% decreased risk of death with IP/IV versus IV chemotherapy)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb2226",
"class":"cell txt l",
"children":[
"Suboptimally debulked stage III disease or stage IV disease",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cbdb6a",
"class":"cell txt l",
"children":[
"Stage III (suboptimal) disease: spread to abdomen with residual masses >1 cm after debulking surgery"
]
},
" ",
{
"type":"p",
"hlId":"e8265b",
"class":"cell txt l",
"children":[
"Stage IV disease: spread beyond abdomen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4af228",
"class":"cell txt l",
"children":[
"Surgery (usually done even for stage IV disease as it improves survival) and chemotherapy; preoperative (neoadjuvant) chemotherapy given for initially unresectable cancer"
]
},
" ",
{
"type":"p",
"hlId":"77ea36",
"class":"cell txt l",
"children":[
"Maintenance olaparib after first-line chemotherapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bb3295",
"class":"cell txt l",
"children":[
"Stage III: 39% relative survival"
]
},
" ",
{
"type":"p",
"hlId":"2f0731",
"class":"cell txt l",
"children":[
"Stage IV: 17% relative survival"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IP = intraperitoneal; IV = intravenous."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Careful staging is critical: almost one third of patients with apparent early disease will have more advanced disease when thorough staging is completed."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Relative survival is the ratio of the proportion of observed survivors in a cohort of patients with cancer to the proportion of expected survivors in a comparable set of cancer-free individuals."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"According to recent guidelines by the American Society of Clinical Oncology and the Society of Gynecologic Oncology, patients with stage IIIC or IV ovarian cancer who are at high perioperative risk or who have a low likelihood of optimal tumor debulking should receive neoadjuvant chemotherapy followed by reevaluation for cytoreductive surgery."
]
]
}